Remix Therapeutics, Massachusetts, United States
Dominic is currently SVP, Head of Drug Discovery at Remix Therapeutics. Dominc has extensive experience in the biotech space and building successful biotech companies. Prior to his current role at Remix therapeutics, recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.
Disclosure information not submitted.
Nucleic Acid-Targeted Therapeutics
Monday, February 5, 2024
10:00 AM – 12:00 PM EST
Reprogramming RNA to target unaddressed disease drivers
Monday, February 5, 2024
11:30 AM – 12:00 PM EST